« Return to News | CROs/Service Providers

Siemens partners with ViiV Healthcare and Tocagen

Thursday, February 9, 2012 08:12 AM

Siemens Healthcare Diagnostics has formed two new companion diagnostics partnerships with pharmaceutical companies ViiV Healthcare and Tocagen—marking a step for Siemens into the fast-growing segment of the in vitro diagnostics market.

Siemens' partnership with ViiV Healthcare will focus on clinical trials related to Celsentri/SelzentryR (maraviroc)—ViiV Healthcare's novel CCR5 co-receptor antagonist for the treatment of CCR5-tropic HIV—followed by potential commercialization of a diagnostics test to assist in patient selection prior to physician treatment decisions, subject to FDA approval.

The Siemens-Tocagen relationship will begin with diagnostic tests to support clinical trials related to Tocagen's unique viral gene therapy (Toca 511 & Toca FC) under investigation for the treatment of primary brain cancer, followed by potential commercialization of diagnostic tests for therapy monitoring, subject to FDA approval.

These partnerships reflect Siemens' efforts to expand its healthcare global presence by leveraging the power of in vivo and in vitro diagnostics to impact therapeutics—one goal of the recently launched Siemens Agenda 2013, a new two-year global initiative.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.